AXIM Biotechnologies, Inc. (OTCQB: AXIM) Rallies 26.56% After Receiving Purchase Order For 50,000 Boxes of Its Proprietary CBD-Based Chewing Gum

AXIM Biotechnologies, Inc.

AXiM Biotechnologies, Inc. (OTCQB: AXIM) is engaged within the research, development, and commercialization of cannabinoid-based pharmaceutical and nutraceutical products. Shares of the cannabis-based treatment company jumped 26.56% during trading on Tuesday, April 23, 2019. Over the past month, AXIM Biotechnologies has seen average daily volume of 166,590 shares. However, volume of 357,235 shares or dollar volume of $578,720, exchanged hands during trading on Tuesday.

Shares of AXIM Biotechnologies jumped on Tuesday, after the company announced that its nutraceutical division has received a purchase order for 50,000 boxes of the company’s proprietary CBD-based chewing gum “from a leading direct-to-consumer company for distribution throughout the United States,” according to the company. The purchase order is in relation to a private-label manufacturing and supply agreement that was executed back on April 12, 2019, which calls for 75,000 boxes per quarter or 300,000 boxes in a calendar year. Here is the full press release detailing of the purchase order:

AXIM Biotechnologies, Inc. Press Release:

NEW YORK, April 23, 2019 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (“AXIM”) (“the Company”) (“AXIM®Biotech”) (OTC: AXIM), a world leader in cannabinoid research and development, today announced that the nutraceutical division of the Company, which produces and distributes cannabinoid-based lifestyle and wellness products, has received a purchase order for 50,000 boxes of its proprietary cannabidiol (CBD)-based chewing gum from a leading direct-to-consumer company for distribution throughout the United States.

The purchase order, pursuant to a private-label manufacturing and supply agreement signed April 12, 2019, describes an ongoing relationship between the two companies and allows for exclusivity if the company orders 75,000 boxes of product per quarter or 300,000 boxes of product in a calendar year. The initial order represents 1.5 million pieces of AXIM’s gum product. With its recently acquired patents for oral compositions containing cannabinoids and topical cream, along with its patent on chewing gum containing cannabinoids including CBD, this order represents a large sales momentum shift as AXIM aims to expand the Company’s nutraceutical division and create revenue for the company.

“While many companies in the burgeoning CBD market compete to provide consumers with various products in similar forms such as tinctures and capsules, AXIM sets itself apart through our patented chewing gum delivery system which has shown to increase bioavailability of the cannabinoids,” said AXIM® Biotech CEO John W. Huemoeller II. “As a part of our strategic short- and mid-term business plan, we have looked to expand the nutraceutical division of our company as a way to generate revenue and apply it toward furthering our clinical development program, while avoiding seeking out other more expensive funding alternatives.”

The CBD market is estimated to grow to $16 billion by 2025 as consumers continue to educate themselves on the cannabinoid’s extensive potential therapeutic benefits. Currently, tinctures account for 44 percent of the market, topicals make up 26 percent, capsules account for 22 percent and beverages compose 19 percent. With this purchase agreement and distribution of AXIM’s proprietary CBD gum under a white label, the Company is essentially creating a new market segment, utilizing a consumer-friendly delivery mechanism, that has the opportunity to capture market share from other forms of CBD products.

To learn more about AXIM® Biotechnologies, Inc., visit http://aximbiotech.com/.

About AXIM® Biotechnologies
AXIM® Biotechnologies, Inc. (AXIM) is a world leader in the research and development of cannabinoid-based pharmaceutical and nutraceutical products. Along with building a robust intellectual property portfolio, AXIM is focused on clinical development programs that bring more efficacy and/or lower side effects than existing alternatives and require small to medium budgets and timelines to bring to market which presents a high added-value to the pharmaceutical field.

AXIM’s flagship products include MedChew® with dronabinol, which is planned to undergo a bioequivalence study to fast track through FDA as an alternative to approved Marinol; MedChew® RL, which is planned to undergo clinical trials for treatment of restless leg syndrome; and MedChew® Rx, a combination cannabidiol (CBD)/tetrahydrocannabinol (THC) functional, controlled-release chewing gum that is planned to undergo clinical trials for the treatment of pain and spasticity associated with Multiple Sclerosis (MS). For more information, please visit www.AXIMBiotech.com.

FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of AXIM Biotechnologies, Inc. to be materially different from the statements made herein.

LEGAL DISCLOSURE
AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).

The post AXIM Biotechnologies, Inc. (OTCQB: AXIM) Rallies 26.56% After Receiving Purchase Order For 50,000 Boxes of Its Proprietary CBD-Based Chewing Gum appeared first on Spotlight Growth.

Source: SpotLight Growth Canabis
AXIM Biotechnologies, Inc. (OTCQB: AXIM) Rallies 26.56% After Receiving Purchase Order For 50,000 Boxes of Its Proprietary CBD-Based Chewing Gum
SpotLight Growth Canabis

Matt Rego
Matt is the Founder and CEO of Spotlight Growth. Prior to launching Spotlight Growth, Matt worked six years within the investor relations industry, most recently serving as Vice President of Sales and Marketing at Global Discovery Group, Inc. In addition, Matt has been a financial writer and analyst since 2010 and investing in the stock market since 2007. Articles and content have appeared on well-known financial websites, such as: Investopedia, Google Finance, Yahoo Finance, ValueWalk, Minyanville, Seeking Alpha, CBS MoneyWatch, Investment Underground, Emerging Growth, Blasting News, GenYWealth, and more. In addition, Matt has received an honorable mention in Barrons’ and the New York Post. Matt graduated from the University of Minnesota with a Bachelor’s Degree in Finance.

Related posts